Pet Scan vs CT Scan: One Shows What It Looks Like, the Other Shows What It's Doing

The Core Difference: Structure vs. Activity

Think of CT as a high-resolution photograph and PET as a heat map. CT excels at showing physical details: the size of a tumor, whether a bone is fractured, how your lungs look. It's fast, widely available, and gives excellent detail for organs like the lungs and bones.

PET works differently. It typically uses a radioactive tracer to highlight areas of unusual metabolic activity or specific receptor targets. Cancer cells, inflamed tissue, and certain infections consume more energy than normal tissue, so they show up as "hot spots." This makes PET exceptionally sensitive for detecting active cancer, inflammation, and metastases that might not yet be large enough to show structural changes on CT.

Where PET/CT Clearly Outperforms CT Alone

Across multiple cancer types, the research consistently shows PET/CT is more sensitive than CT alone for catching metastases and recurrence. The gap is sometimes dramatic.

• Breast cancer: PET/CT picks up recurrence and metastases with roughly 95% sensitivity, compared to about 80% for CT. That 15-percentage-point difference represents real missed cases.
• Lymphoma: PET/CT detects involved regions with approximately 97% sensitivity versus 88% for contrast-enhanced CT. Beyond raw detection, PET/CT leads to more accurate staging and more frequent stage changes, meaning patients get reclassified into a different disease stage that may require a completely different treatment approach.
• Prostate and colorectal cancer: Specialized PET tracers (like PSMA-PET for prostate cancer) outperform CT for identifying nodal and distant metastases.
• Ovarian cancer: Here the story is slightly different. PET/CT and contrast CT have similar sensitivity, but PET/CT is more specific, meaning fewer false positives. When a scan says something looks suspicious, PET/CT is more likely to be right about it.
• The pattern across these cancers is consistent: PET/CT generally catches more disease and produces fewer equivocal, "we're not sure what this is" findings. That clarity often changes staging and treatment decisions substantially.

When CT Alone Still Makes More Sense

Despite PET/CT's advantages, CT remains the workhorse of medical imaging for good reasons.

• Routine surveillance in lower-risk settings. If you're being monitored after cancer treatment and your risk profile is moderate, CT is typically the go-to. It's faster, cheaper, more widely available, and provides the anatomical detail needed for straightforward follow-up.
• First-line imaging. When doctors need an initial look at what's going on, CT is almost always the starting point. It answers the structural question first: Is there a mass? How big? Where exactly?
• Surgical planning. Surgeons need precise anatomy. CT delivers that.
• Abdominal and pelvic disease when anatomy is the key question. If the clinical situation is relatively straightforward, CT handles it well without the added cost and radiation of PET.

There's also a specificity issue that works against PET in certain contexts. Because PET highlights metabolic activity, inflammation can mimic cancer on a PET scan, producing false positives. CT doesn't have this particular problem.

The Cost and Radiation Tradeoff

PET/CT generally delivers a higher radiation dose than CT alone. Many centers use full-dose diagnostic CT as the CT component within a PET/CT scan rather than lower-dose protocols, which adds to the total exposure.

Cost is the other significant factor. PET/CT is substantially more expensive, and not every facility has one. For situations where CT provides sufficient information, the added expense and radiation of PET/CT aren't justified.

That said, when PET/CT changes your stage or treatment plan, which it frequently does in aggressive or complex cancers, the cost becomes easier to justify. A scan that prevents unnecessary surgery or catches hidden metastases before treatment starts pays for itself in clinical terms.

How Doctors Decide Which Scan You Get

The decision between CT alone and PET/CT comes down to what question your doctor is trying to answer and how high the stakes are.

CT alone is typically chosen when:

• It's an initial workup and the first look at a problem
• You're in routine surveillance after cancer treatment in a moderate-risk scenario
• The main question is anatomical (size, location, surgical landmarks)

PET/CT is typically chosen when:

• You're being staged for an aggressive cancer like lymphoma, advanced breast cancer, cervical, pancreatic, colorectal, or certain lung and prostate cancers
• There's suspected recurrence or something unclear showed up on CT or MRI
• You have a fever or inflammation of unknown origin and other tests haven't provided answers

The research makes clear that PET/CT isn't a "better version" of CT. It's a different tool that layers functional information on top of anatomy. In straightforward situations, that extra layer isn't needed. In complex or high-risk situations, it can be the difference between the right treatment plan and the wrong one.

Putting This Into a Decision Framework

If you're facing a scan decision, or wondering why your doctor ordered one type over the other, here's the practical logic:

CT is the foundation. PET/CT is the problem-solver you bring in when the stakes are high, the picture is unclear, or you need to know not just what something looks like, but whether it's active. If your doctor recommends one over the other, the reasoning almost certainly fits one of these patterns.